Product Overview
Ipamorelin: Targeted Support for Natural Growth Hormone Release
What Ipamorelin Is Ipamorelin is a pentapeptide—just five amino acids long—with the sequence Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂.
It is a synthetic peptide designed to mimic ghrelin, the natural hormone produced in the stomach that signals hunger and triggers growth hormone (GH) release. Ghrelin helps regulate metabolism, energy balance, and tissue repair; Ipamorelin is a refined version that focuses almost exclusively on the GH pathway.
Why Ipamorelin Is of Special Research Interest
As natural GH levels decline with age, many individuals experience slower recovery, reduced muscle tone, increased body fat, lower energy, and changes in sleep or bone strength. Ipamorelin encourages the body to release its own natural GH—rather than supplying external hormone—making it a selective, physiologic option in research settings.
How It Works (Mechanism of Action)
Ipamorelin selectively binds to ghrelin receptors (growth hormone secretagogue receptors) in the pituitary gland. This gently stimulates natural GH pulses—similar to the body’s own rhythm—without increasing cortisol, ACTH, prolactin, FSH, LH, or TSH.
Potential Benefits Shown in Limited Research
Early research (mostly pre‑clinical and small pilot human studies) has explored Ipamorelin’s effects beyond basic GH release. These findings are preliminary and not from large‑scale human trials:
-
Increased longitudinal bone growth and bone mass in animal models
-
Dose‑dependent improvements in tibia growth rates and bone formation
-
Clear, short‑term increases in GH pulses in healthy human volunteers
-
Predictable pharmacokinetics with good tolerability in repeated dosing scenarios
Backed by Science
-
Pre‑clinical studies in pituitary cell cultures, rats, and pigs showed Ipamorelin strongly stimulates GH release with potency similar to other secretagogues, but uniquely does not elevate ACTH or cortisol, even at high doses (Raun et al., Eur J Endocrinol, 1998).
-
Human volunteer studies confirmed that intravenous Ipamorelin produces dose‑dependent GH pulses (peak ~40 minutes), with a short ~2‑hour half‑life and no unexpected hormone changes (Raun et al., Pharm Res, 1999).
Stacking Note
Ipamorelin has been discussed in stacks with other peptides. These combinations may potentially provide enhanced results depending on the research indication. Findings remain limited and require further human studies for safety and efficacy. Human clinical data remains limited, and Ipamorelin is not FDA‑approved for therapeutic use; it is primarily researched or used off‑label/investigationally.
Disclaimer
Peptides are sold for laboratory research use only. They are not for human, medical, or veterinary use. Buyers must be qualified to handle research materials and assume full responsibility for their safe use.